Nancy M. Espinal

FDA investigator

Appears on 16 documents from 2016 to 2022, mostly at sites in New Jersey. Most often cites production record review (21 CFR 211.192).

16
Documents on file
6.8
Observations per 483
2016
First seen
2022
Most recent

What they cite most

From 109 observations

Activity by year

2016: 2, 2017: 2, 2018: 1, 2019: 5, 2020: 2, 2021: 3, 2022: 1

Where

New Jersey 11 · India 2 · France 1 · Massachusetts 1 · Pennsylvania 1

Is Nancy M. Espinal coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

16 documents, newest first
FirmOpen
483 CIS Bio InternationalDec 16, 2022 · Gif sur Yvette, France
483 Dr. Reddy's Laboratories Ltd.Oct 29, 2021 · Duvvada, India
483 Symed Labs LimitedOct 16, 2021 · Yadadri Bhuvangiri, India
483 Teligent, Inc.Aug 31, 2021 · Buena, New Jersey
483 EHT Pharmacy LLC dba CurexaOct 9, 2020 · Egg Harbor Township, New Jersey
483 KVK-TECH, INC.Mar 13, 2020 · Newtown, Pennsylvania
483 AptaPharma Inc.Sep 25, 2019 · Pennsauken, New Jersey

About this profile

What does Nancy M. Espinal inspect?

Nancy M. Espinal appears on 16 documents on file covering 14 sites, mostly in New Jersey.

What do they cite most often?

21 CFR 211.192 (production record review), followed by 21 CFR 211.160 and 21 CFR 211.194.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Nancy M. Espinal is dated Dec 16, 2022.

FDA Investigator Nancy M. Espinal: 483s & Inspections · FDA Intel